Q-omics provides the consensus-scored MIR765 profile across patient tissues and cancer cell-line models. MIR765 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, MIR765 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, MIR765 RNA expression shows 14,994 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight DLBC, KIRC, and THYM as cancer lineages where MIR765 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR765 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR765 survival associations across molecular data types. MIR765 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR765 RNA expression–survival associations across cancer types. High MIR765 expression shows unfavorable associations in DLBC, KIRC, THCA, LIHC, SKCM and ACC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify DLBC as the clearest survival context for MIR765 RNA expression.
This table summarizes MIR765 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR765. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR765 shows lower tumor expression in KIRC and LUSC and higher tumor expression in LIHC, CHOL, BLCA and READ. The KIRC box plot shows higher MIR765 RNA expression in normal versus tumor tissue (log2 FC = −0.686, t-test p < 0.001).
This table shows molecular features associated with MIR765 in patient tissues and cancer cell lines. In patient samples, MIR765 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
